Prostate-Specific Antigen (PSA) Levels and Prostate Cancer Risk

Introduction to PSA and Prostate Cancer

The American Urological Association suggests that PSA is a valuable tumor marker for prostate cancer with multiple clinical applications, including screening, diagnosis, risk stratification, and monitoring treatment response 1, 2

Age-specific reference ranges have been established, with normal levels varying by age and ethnicity:
- 40-49 years: 0-2.5 ng/mL for whites, 0-2.0 ng/mL for African-Americans and Asian-Americans 5, 4
- 50-59 years: 0-3.5 ng/mL for whites, 0-4.0 ng/mL for African-Americans, 0-3.0 ng/mL for Asian-Americans 5, 4
- 60-69 years: 0-4.5 ng/mL for whites and African-Americans, 0-4.0 ng/mL for Asian-Americans 5, 4
- 70-79 years: 0-6.5 ng/mL for whites, 0-5.5 ng/mL for African-Americans, 0-5.0 ng/mL for Asian-Americans 5, 4
The risk of prostate cancer increases with higher PSA levels, with approximately 10% risk of prostate cancer at PSA 0-2.0 ng/mL, 15-25% risk at PSA 2.0-4.0 ng/mL, 17-32% risk at PSA 4.0-10.0 ng/mL, and 43-65% risk at PSA >10.0 ng/mL 1, 3

A continuum of prostate cancer risk exists even at traditionally low PSA values, with cancer detection rates of 6.6% at PSA ≤0.5 ng/mL, increasing to 26.9% at PSA 3.1-4.0 ng/mL 5, 3
PSA levels correlate with disease extent, with approximately 80% of men with PSA <4.0 ng/mL having organ-confined disease, 70% with PSA 4.0-10.0 ng/mL having organ-confined disease, and 50% with PSA >10.0 ng/mL having organ-confined disease 1

The proportion of men with metastases to pelvic lymph nodes increases with PSA levels, with approximately 5% having lymph node metastases at PSA ≤10.0 ng/mL, 18% at PSA 10.0-20.0 ng/mL, and 36% at PSA >20.0 ng/mL 1

For each 2-point increase in PSA level, the risk of biochemical progression after surgery increases approximately 2-fold 1, 3
Recurrence of cancer within 10 years of surgery occurs in approximately 10% of men with preoperative PSA <2.6 ng/mL, 20% with preoperative PSA 2.6-10.0 ng/mL, and 50% with preoperative PSA >10.0 ng/mL 1, 3
PSA velocity (PSAV) >2.0 ng/mL/year in the year before diagnosis is associated with approximately 10-fold greater risk of death from prostate cancer in the decade after radical prostatectomy 1, 3

Bone scans are generally not necessary in patients with newly diagnosed prostate cancer who have PSA <20.0 ng/mL unless clinical examination suggests bony involvement 1, 3
CT or MRI may be considered for staging when PSA >20.0 ng/mL or when Gleason score ≥8 1, 3
Pelvic lymph node dissection may not be necessary if PSA <10.0 ng/mL and Gleason score ≤6 1, 7

5α-reductase inhibitors (finasteride, dutasteride) reduce PSA levels by approximately 50% after 6-12 months of therapy; PSA values should be doubled for comparison with normal ranges 3
Recent urinary catheterization, prostatitis, ejaculation, and trauma can transiently elevate PSA levels 6, 3

The U.S. Preventive Services Task Force does not recommend routine PSA-based screening 6, 8
Most professional organizations recommend shared decision-making regarding PSA screening, taking into account individual risk factors 6, 8
Men with elevated risk (African Americans, family history) should consider beginning screening at age 45 6, 3